Zydus received FDA approval to conduct a Phase 2b trial testing usnoflast, its oral therapy for ALS, in 210 patients.
Sun Pharmaceutical Industries Ltd. key Products/Revenue Segments include Pharmaceuticals and Other Operating Revenue for the year ending 31-Mar-2024.For the quarter ended 30-09-2024, the company has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback